Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study. Issue 2 (February 2023)

• Record Type: Journal Article
• Authors: Macaluso, Fabio Salvatore; Principi, Mariabeatrice; Facciotti, Federica; Contaldo, Antonella; Todeschini, Alessia; Saibeni, Simone; Bezzio, Cristina; Castiglione, Fabiana; Nardone, Olga Maria; Spagnuolo, Rocco; Fantini, Massimo Claudio; Riguccio, Gaia; Caprioli, Flavio; Viganò, Chiara; Felice, Carla; Fiorino, Gionata; Correale, Carmen; Bodini, Giorgia; Milla, Monica; Scardino, Giulia; Vernero, Marta; Desideri, Federico; Mannino, Mariella; Rizzo, Giuseppe; Orlando, Ambrogio; Amato, Arnaldo; Ascolani, Marta; Calabrese, Giulio; Casà, Angelo; Comberlato, Michele; Conforti, Francesco Simone; De Bona, Manuela; Demarzo, Maria Giulia; Doldo, Patrizia; Dragoni, Gabriele; Furfaro, Federica; Mulinacci, Giacomo; Olmo, Oriana; O'Sed, Nicole Piazza; Paba, Salvatore; Radice, Simona; Renna, Sara; Ribaldone, Davide Giuseppe; Rizzuto, Giulia;
• Is Part Of: Digestive and liver disease. Volume 55:Issue 2(2023)
• Page Start: 154
• Page End: 159
• Publication Date: 2023-02
• Subjects: Biologics -- SARS-CoV-2 -- Vaccines; Digestive organs -- Diseases -- Periodicals; Liver -- Diseases -- Periodicals; 616.33005
• DOI: 10.1016/j.dld.2022.08.027
• Languages: English
• ISSNs: 1590-8658

Abstract

Abstract: Background: Patients on immunosuppressive drugs have been excluded from COVID-19 vaccines trials, creating concerns regarding their efficacy. Aims: To explore the humoral response to COVID-19 vaccines in patients with inflammatory bowel disease (IBD) Methods: E ffectiveness and S afety of C OVID-19 Va ccine in P atie nts with I nflammatory B owel D isease (IBD) Treated with Immunomodulatory or Biological Drugs (ESCAPE-IBD) is a prospective, multicentre study promoted by the Italian Group for the study of Inflammatory Bowel Disease. We present data on serological response eight weeks after the second dose of COVID-19 vaccination in IBD patients and healthy controls (HCs). Results: 1076 patients with IBD and 1126 HCs were analyzed. Seropositivity for anti-SARS-CoV-2 IgG was reported for most IBD patients, even if with a lesser rate compared with HCs (92.1% vs. 97.9%; p<0.001). HCs had higher antibody concentrations (median OD 8.72 [IQR 5.2-14-2]) compared to the whole cohort of IBD patients (median OD 1.54 [IQR 0.8-3.6]; p<0.001) and the subgroup of IBD patients (n=280) without any treatment or on aminosalicylates only (median OD 1.72 [IQR 1.0–4.1]; p<0.001). Conclusions: Although most IBD patients showed seropositivity after COVID-19 vaccines, the magnitude of the humoral response was significantly lower than in HCs. Differently from other studies, these findings seem to be mostly unrelated to the use of immune-modifying treatments (ClinicalTrials.govID:NCT04769258).